News in Gastric Cancer

News from around the world, curated by the Gastric Cancer Foundation.
Manufacturer's illustration of how Keytruda stops cancer cells hiding from the immune system.

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma

Merck received FDA approval for Keytruda plus chemotherapy for some patients with advanced esophageal or gastroesophageal junction cancer.

Read Source